How the U.S. Compares to Europe on Biosimilar Approvals and Products In the Pipeline – Updated January 13, 2025
FDA and EMA both approve biosimilar versions of Stelara® (ustekinumab), Eylea® (aflibercept) and Prolia® and Xgeva® (denosumab). FDA approves 19 biosimilars in 2024. Biosimilars, once a niche segment in the pharmaceutical industry, are now making a …